|
WO2021016637A1
|
|
Compositions for treatment of substance use disorder
|
|
WO2020132496A1
|
|
Nitric oxide donor and anti-oxidant compounds
|
|
WO2020106605A1
|
|
Reconstituted hdl nanoparticles for delivery of radioactive agents and uses thereof
|
|
WO2020081642A1
|
|
Process for engineering targeted nanoparticles
|
|
US2019327958A1
|
|
Devices, Systems, and Methods for Modeling Ocular Translaminar Pressure Gradients
|
|
WO2019051419A1
|
|
Engineered cas9 variants
|
|
US2019071505A1
|
|
Compositions and methods for activation of nk cells killing of prostate cancer and breast cancer cells
|
|
WO2019036417A2
|
|
Inhibition of ngly1 for the treatment of cancer
|
|
US2020216847A1
|
|
Inhibition of let7i as a means to enhance the protective effect of progesterone against stroke
|
|
WO2018232258A1
|
|
Reprogramming fibroblasts to retinal cells
|
|
WO2018195382A1
|
|
Enhanced therapeutic agent and nucleic acid delivery via hdl or reconstituted hdl nanoparticles
|
|
US2017165200A1
|
|
Composition of lipid-based nanoparticles for small molecules and macromolecules
|
|
US2017112775A1
|
|
Situ self-assembling pro-nanoparticle compositions and methods of preparation and use thereof
|
|
US2015011406A1
|
|
Multiple-pulse pumping for enhanced fluorescence detection and molecular imaging in cells and tissue
|
